The AANS/CNS Drugs and Devices Committee is actively engaged with the Food and Drug Administration (FDA) and other scientific, governmental, clinical and industry representatives to provide neurosurgical expertise on drugs, devices and biologics used to treat patients and to foster innovation and patient safety. These activities include recommending neurosurgeon experts to serve on the FDA Advisory panels, providing input on FDA Guidance Documents and testimony at panel meetings, as appropriate. In addition, organized neurosurgery is an official partner with the FDA's Network of Experts program to provide rapid clinical assistance to FDA reviewers. The AANS and CNS continue to advocate policies that will decrease the regulatory burden for medical-device innovation and ensure patient access to new and improved medical technology.
Letters
Published: December 3, 2018
Dear Administrator Verma: The undersigned physician organizations representing both national medical societies and state medicalsocieties are writing in response to the Centers for Medicare & Medicaid Services (CMS) request forfeedback […]
Letters
Published: September 18, 2018
Dear Leader McConnell, Leader Schumer, Speaker Ryan, and Leader Pelosi: Thank you for your leadership in combatting the opioid epidemic. The undersigned organizations represent adiverse group of stakeholders across the […]
Letters
Published: September 18, 2018
Dear Chairman Walden and Ranking Member Pallone: The undersigned organizations, representing a cross-section of medical specialties, write toreiterate our strong support for protecting our patients by aligning 42 CFR Part […]
Article
Published: September 7, 2018
Re: Memo of August 7th Regarding Prior Authorization and Step Therapy for Part B Drugs inMedicare Advantage The undersigned organizations representing physicians thank the Centers for Medicare and MedicaidServices (CMS) […]
Letters
Published: August 16, 2018
Subject: Docket FDA-2018-N-1315 Medical Device Safety Action Plan: ProtectingPatients and Promoting Public Health. Dear Dr. Gottlieb, The American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons(CNS) appreciate the […]
Article
Published: August 9, 2018
In 2014, the AMA Opioid Task Force convened to coordinate efforts that were underway withinorganized medicine to help end the nation’s opioid epidemic. Together, the Task Force identifiedsix recommendations focused […]
Letters
Published: March 27, 2018
SUBJECT: H.R. 4482, the Opioid Abuse Deterrence, Research, and Recovery Act Dear Representatives Meadows and Renacci: On behalf of the American Association of Neurological Surgeons (AANS) and Congress of NeurologicalSurgeons […]
Letters
Published: March 20, 2018
SUBJECT: H.R.5311, the CARA 2.0 Act of 201 Dear Representatives Blackburn, Ryan, MacArthur and Kuster: On behalf of the American Association of Neurological Surgeons (AANS) and Congress of NeurologicalSurgeons (CNS), […]
Letters
Published: March 15, 2018
RE: Response to the Opioid Crisis Dear Chairman Brady, Ranking Member Neal, Chairman Roskam, and Ranking Member Levin: The Alliance of Specialty Medicine (the “Alliance”) represents more than 100,000 specialty […]
Letters
Subject: CMS-2017-0163, Advance Notice of Methodological Changes for Calendar Year(CY) 2019 for Medicare Advantage (MA) Capitation Rates, Part C and Part DPayment Policies and 2019 Draft Call Letter Dear Administrator […]
Article
Preview not available… … Read full article here
Article
Appropriate and reasonable regulatory decisions have provided access to groundbreaking newtechnologies for the treatment of brain aneurysms. These technologies have dramaticallyimproved patient care over the past two decades, ushering in […]
Letters
Published: February 28, 2018
SUBJECT: S. 2456, CARA 2.0 Act of 2018 Dear Senators Portman, Whitehouse, Capito, Klobuchar, Sullivan, Hassan, Cassidy and Cantwell: On behalf of the American Association of Neurological Surgeons (AANS) and […]